GT Biopharma
GTBP
17 hedge funds and large institutions have $222K invested in GT Biopharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 16 → 17 (+1)
4.21% more ownership
Funds ownership: 6.31% → 10.52% (+4.2%)
69% less capital invested
Capital invested by funds: $711K → $222K (-$489K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$213K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$59.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25.5K |
| 4 |
Morgan Stanley
New York
|
+$14.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$94.2K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9.52K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.74K |
| 4 |
MYIA
Mount Yale Investment Advisors
Denver,
Colorado
|
-$165 |
| 5 |
FRA
Front Row Advisors
Tiburon,
California
|
-$4 |
GTBP Hedge Fund Activity: Q3 2025 in Review
17 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2025, worth a combined $222K — down 69% from $711K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GTBP positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $213K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $94.2K sold.
- 17 institutional investors held GT Biopharma (GTBP) as of Q3 2025, up from 16 in Q2 2025.
- Funds reported $222K of GT Biopharma stock for Q3 2025, down 69% quarter-over-quarter.
- 3 funds opened new GT Biopharma positions in Q3 2025 and 2 closed out, a net change of +1 holder.
- The largest GT Biopharma buyer in Q3 2025 was DRW Securities, an estimated $213K added.
- The largest GT Biopharma seller in Q3 2025 was Renaissance Technologies, an estimated $94.2K sold.
Based on aggregated 13F filings for Q3 2025.